Naslov
COVID-19 i hipertenzija
(COVID-19 and hypertension)

Autori
Grinžek, Tajana ; Nikolina, Kolobarić ; Šušnjara, Petar ; Haršanji Drenjančević, Ivana

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, neobjavljeni rad, ostalo

Skup
Svjetski dan hipertenzije

Mjesto i datum
Osijek, Hrvatska, 17.05.2021

Vrsta sudjelovanja
Poster

Vrsta recenzije
Domaća recenzija

Ključne riječi
hipertenzija ; COVID-19 ; angiotenzin II ; inhibitori spike proteina
(hypertension ; COVID-19 ; angiotensin II ; spike protein inhibitors)

Sažetak
Covid-19 is a viral infectious disease caused by the SARS-Cov-2 virus. It is highly transmissible, rapidly escalating and spread into a global pandemic. Early reports from major episodes of COVID-19, including Wuhan and Lombardy in Italy, revealed higher morbidity and mortality rates among patients with hypertension. Since SARS-CoV-2 infects human cells via the angiotensin-converting enzyme II (ACE2) receptor that acts on the renin- angiotensin-aldosterone system (RAAS), a key regular of blood pressure there is posible link beetwen hypertension and Covid -19. SARS-CoV-2 binds to the ACE2 receptor via its spike (S) protein to allow entry into host cells. This complex is endocytosed leading to down- regulation of ACE2 and resulting in local accumulation of angiotensin II. Severe respiratory illness is a hallmark of COVID-19 and a primary cause of morbidity- and mortality. Concerns have been raised about the potential risk associated with RAAS inhibitors. It is debated if inhibitors contrube to infection or facilitating COVID -19. In conclusion, there is as yet no evidence that hypertension is related to outcomes of COVID- 19, or that ACE inhibitor or ARB use is harmful, or for that matter beneficial, during the COVID-19 pandemic.

Izvorni jezik
Hrvatski, engleski

Znanstvena područja
Javno zdravstvo i zdravstvena zaštita

POVEZANOST RADA